Option Care posts early sales figures for Q4 and 2024, guides above views

 

• Ahead of 43rd Annual J.P. Morgan Healthcare Conference, Option Care Health (NASDAQ:OPCH) reported Q4 net revenue of approximately $1.34 billion to $1.35 billion, representing approximately 19.2% to 20.1% growth over the fourth quarter of 2023, against consensus of $1.27 billion.
• Net income of approximately $56.8 to $60.9 million, or diluted earnings per share of $0.33 to $0.36.
• Adjusted net income of approximately $71.0 million to $76.8 million, or adjusted diluted earnings per share of $0.42 to $0.45 much higher than consensus of $0.32.
• Adjusted EBITDA of approximately $118.7 million to $121.7 million, representing approximately a 6.4% to 9.1% increase over the fourth quarter of 2023
• FY24 preliminary net revenue of approximately $4.99 billion to $5.00 billion ($4.92 billion), representing approximately 16.0% to 16.2% growth over the prior year.
• Net income of approximately $208.5 million to $212.6 million, or diluted earnings per share of $1.21 to $1.23
• Adjusted net income of approximately $268.3 million to $274.1 million, or adjusted diluted earnings per share of $1.55 to $1.59 compared to consensus of $1.20.
• Adjusted EBITDA of approximately $441.0 million to $444.0 million, representing approximately a 3.7% to 4.4% increase over the prior year
• Cash flow from operations of at least $300 million
• Cash and cash equivalents of approximately $412.6 million
• The company expects FY25 net revenue of $5.2 billion to $5.4 billion vs $5.23 billion consensus
• Adjusted EBITDA of $445 million to $465 million
• Adjusted EPS of $1.59 to $1.69 ($1.22 consensus), including negative gross profit impact of approximately $60 million to $70 million dollars related to the Stelara pricing adjustments.
• The Company expects to reports Q4 and FY24 results on February 26, 2025.

https://www.msn.com/en-us/money/companies/option-care-posts-early-sales-figures-for-q4-and-2024-guides-above-consensus/ar-BB1rmPkL